![]() ![]() Obtain a pre-treatment cardiovascular examination including an ECG in all patients. Torsades de pointes and ventricular tachycardia have been reported with anagrelide. Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION: CONTENTS * 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Starting Dose 2.2 Dose Titration Based Upon Platelet Response 2.3 Dose Modifications for Hepatic Impairment 2.4 Clinical Monitoring 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Cardiovascular Toxicity 5.2 Pulmonary Hypertension 5.3 Bleeding Risk 5.4 Pulmonary Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Drug that Prolong QT 7.2 PDE3 Inhibitors 7.3 Aspirin and Drugs that Increase Bleeding Risk 7.4 CYP450 Interactions 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |